Table 6.
Association of Calpain 10 SNP 19 genotypes with biochemical markers in T2DM in diabetic nephropathy patients (n = 80).
| Genotypes | 11 (No. 27) |
12 (No. 35) |
22 (No. 18) |
p-Value | P1 | P2 | P3 | |
|---|---|---|---|---|---|---|---|---|
| Variables | ||||||||
| Serum glucose (mg/dL) |
270 ± 97.5 | 256.1 ± 83.8 | 285.8 ± 64.1 | 0.37 | 0.46 | 0.48 | 0.16 | |
| HbA1c (%) | 7.06 ± 0.49 | 7.39 ± 0.49 | 7.41 ± 0.53 | 0.017 | 0.01 | 0.02 | 0.90 | |
| Urea (mmol/L) |
16.9 ± 10.45 | 22.3 ± 12.3 | 15.8 ± 6.8 | 0.055 | 0.045 | 0.34 | 0.001 | |
| Creatinine (μmol/L) |
248.07 ± 169.5 | 431.5 ± 308.9 | 189.4 ± 96.6 | 0.001 | 0.003 | 0.40 | 0.001 | |
| eGFR (mL/min/1.73 m2) |
79.5 ± 8.3 | 79.3 ± 10.3 | 82.8 ± 7.9 | 0.37 | 0.95 | 0.18 | 0.22 | |
| Albuminuria | 132.3 ± 42.1 | 127.6 ± 74 | 104.2 ± 60.4 | 0.14 | 0.71 | 0.06 | 0.11 | |
| Serum TGF-β (ng/mL) |
5.4 ± 0.9 | 5.5 ± 0.9 | 6.0 ± 4 1.2 | 0.13 | 0.59 | 0.05 | 0.11 | |
| Serum IL-17 (pg/mL) |
84.5 ± 27.8 | 85.8 ± 27.5 | 82.7 ± 24.5 | 0.92 | 0.84 | 0.83 | 0.16 | |
| Serum Zn (µg/dL) |
66.8 ± 11.9 | 61.4 ± 13.4 | 72.8 ± 19.3 | 0.027 | 0.15 | 0.17 | 0.008 | |
| Serum Cu (µg/dL) |
231 ± 48.2 | 233 ± 48.5 | 205 ± 30.2 | 0.097 | 0.95 | 0.06 | 0.044 | |
| Serum Mg (µg/dL) |
1.7 ± 0.20 | 1.6 ± 0.21 | 1.7 ± 0.24 | 0.28 | 0.21 | 0.78 | 0.16 | |
| Cu/Zn ratio |
3.5 ± 1.2 | 3.9 ± 1.1 | 3.05 ± 0.08 | 0.033 | 0.18 | 0.16 | 0.01 | |
| MiRNA-375 fold change | 2.8 ± 1.5 | 3.1 ± 2.2 | 3.2 ± 1.9 | 0.74 | 0.53 | 0.49 | 0.86 | |
Data are expressed as means ± SD. The one-way analysis of variance (ANOVA) test followed by the post hoc test was utilised for comparison of means of groups. P1: significance of genotype 11 against 12. P2: significance of genotype 11 against genotype 22. P3: significance between genotypes 12 and 22.